Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

*仅供医学专业人士阅读参考虽然胰高血糖素样肽-1受体激动剂（GLP-1 RA）最初开发是用于治疗2型糖尿病，但在研究中，研究人员发现，GLP-1 RA还能够帮助超重和肥胖患者减重，效果十分显著，并且与是否合并糖尿病无关。美国食品药品监督管理局（FDA ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...